News

Four Imaging and Diagnostic Platforms Making the Move Toward More Individualized Treatment

By Steve Lenier | May 22, 2019

Imaging and diagnostics in ophthalmology are moving toward more individualized patient treatment, with quicker and more detailed diagnoses leading to improved and more specific treatment…

Read More
Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

By Michelle Dalton | May 14, 2019

VANCOUVER – Novartis is one of the world’s largest ophthalmic pharmaceutical companies, with $4.6 billion in assets as part of the Medicines division, yet some…

Read More
A Dozen Takeaways from OIS@ASCRS 2019

A Dozen Takeaways from OIS@ASCRS 2019

By Steve Lenier | May 8, 2019

Last week’s OIS@ASCRS 2019 saw a record number of registrants, and the 650 attendees were treated to a wealth of information from the presenting companies,…

Read More
Protocol V, LEAVO Among Retina Highlights at ARVO

Protocol V, LEAVO Among Retina Highlights at ARVO 2019

By Michelle Dalton | May 1, 2019

VANCOUVER – Leave it to ARVO 2019 – the Association for Research in Vision and Ophthalmology – to keep attendees waiting until mid-evening to hear…

Read More
How OIS@ASCRS 2019 Breaks the Mold

OIS@ASCRS Features New Sessions, Companies

By Steve Lenier | April 24, 2019

OIS@ASCRS 2019 will convene next Thursday, May 2, preceding the American Society of Cataract and Refractive Surgery annual meeting in San Diego. This year’s OIS@ASCRS…

Read More
FDA Forum Sounds Call for OCT Standards

Takeaway from FDA Imaging Forum: Need for Consensus Standards for Optical Coherence Tomography

By Priscilla Villarreal | April 17, 2019

Continued advances in optical coherence tomography are generating excitement for more precise and earlier diagnosis of eye disease, but more research and industry agreement on…

Read More
Will Dexycu’s Cost Inhibit Its Use?

Will Dexycu’s Cost Inhibit Its Use?

By Steve Lenier | April 10, 2019

Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island, recently performed the first cataract surgery in the country using Dexycu (EyePoint Pharmaceuticals), administered as a…

Read More
OIS Index

OIS Index Delivers Stellar First-Quarter 2019 Performance

By Michael Lachman | April 3, 2019

The OIS Index of ophthalmic stocks solidly outperformed its market benchmarks in the first quarter of 2019, gaining 37.1%. During Q1, the overall US stock…

Read More
Dr. Mark Blumenkranz Previews Panel on OCT Imaging and Forum on Laser-Based Imaging

Dr. Mark Blumenkranz Previews Panel on OCT Imaging and Forum on Laser-Based Imaging

By Priscilla Villarreal | March 28, 2019

Regulatory and reimbursement issues surrounding laser-based imaging modalities such as optical coherence tomography and adaptive optics, as well as the emerging role of artificial intelligence…

Read More
Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

By Heather Johnson | March 19, 2019

SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make…

Read More
Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

By Rich Kirkner | March 13, 2019

It didn’t take Biogen long to jump back into ophthalmology after announcing its intention in December 2018 to terminate a collaborative agreement with Applied Genetic…

Read More
Larry Haimovitch, 72, of Mill Valley, California

Larry Haimovitch, 72, Journalist, Advisor and Ophthalmology Leader

By Rich Kirkner | March 13, 2019

Larry Haimovitch, 72, Journalist, Advisor and Ophthalmology Leader Larry Haimovitch, 72, husband of Carie Harris Haimovitch, of Mill Valley, California, died peacefully at home February…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.